# Albumin-bound paclitaxel–induced stromal reprogramming drives resistance to neoadjuvant chemotherapy in patients with pancreatic cancer

Source: [science.org](https://www.science.org/doi/abs/10.1126/scitranslmed.aee4086?af=R) · 2026-11-11 · Medicine
Page: https://themorning.science/story/albumin-bound-paclitaxel-induced-stromal-reprogramming-drives-resistance-to-neoa-9d91f68d9ad3fbd6
Kind: research · Impact: medium

## In brief

- A study in Science Translational Medicine reports that albumin-bound paclitaxel can induce stromal reprogramming in pancreatic tumours.
- The stromal reprogramming is linked to resistance to neoadjuvant chemotherapy in patients with pancreatic cancer.
- The paper was published in Volume 18, Issue 875 of the journal in November 2026.

## Why it matters

It points to the tumour stroma, not only the cancer cells, as a possible driver of poor response to neoadjuvant chemotherapy, which could inform how treatment regimens are designed for pancreatic cancer patients.

## Timeline

- 2026-11-11: Study published in Science Translational Medicine

## Coverage

- [Albumin-bound paclitaxel–induced stromal reprogramming drives resistance to neoadjuvant chemotherapy in patients with pancreatic cancer](https://www.science.org/doi/abs/10.1126/scitranslmed.aee4086?af=R) — science.org, 2026-11-11

Tags: pancreatic cancer, chemotherapy resistance, paclitaxel, tumor stroma, neoadjuvant therapy

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science